MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

type 2 inflammation

Search medical newsFind research, conditions and clinical updates
  • Home
  • type 2 inflammation
Dupilumab Enhances Lung Function in COPD Patients with Type 2 Inflammation: Insights from BOREAS and NOTUS Trials
Posted inClinical Updates Respiratory

Dupilumab Enhances Lung Function in COPD Patients with Type 2 Inflammation: Insights from BOREAS and NOTUS Trials

Posted by By MedXY 11/15/2026
Dupilumab significantly improves lung function parameters in COPD patients with type 2 inflammation, demonstrating sustained benefits regardless of smoking status or emphysema presence.
Read More
Mepolizumab and Blood Eosinophil Variability in COPD: A New Dimension in Targeted Therapy
Posted innews Respiratory

Mepolizumab and Blood Eosinophil Variability in COPD: A New Dimension in Targeted Therapy

Posted by By MedXY 06/13/2026
This article reviews mepolizumab efficacy in COPD patients with variable blood eosinophil counts, showing benefits even with intermittent eosinophilia, expanding treatable phenotypes beyond persistent elevation.
Read More
IL-13 Inhibition with Cendakimab: A New Frontier in Eosinophilic Esophagitis Management
Posted inAllergy & Immunology Gastroenterology news

IL-13 Inhibition with Cendakimab: A New Frontier in Eosinophilic Esophagitis Management

Posted by By MedXY 12/31/2025
A Phase 3 trial demonstrates that cendakimab significantly reduces dysphagia days and improves histologic and endoscopic markers in patients with eosinophilic esophagitis, offering a targeted therapeutic approach for this chronic type 2 inflammatory condition.
Read More
Decoding COPD Heterogeneity: Airway Eosinophilia, Type 2 Inflammation, and Corticosteroid Responsiveness
Posted innews Respiratory Specialties

Decoding COPD Heterogeneity: Airway Eosinophilia, Type 2 Inflammation, and Corticosteroid Responsiveness

Posted by By MedXY 09/19/2025
This study elucidates that airway eosinophilia in COPD is linked to enhanced type 2 inflammation in airway epithelium and predicts responsiveness to inhaled corticosteroids, revealing a distinct COPD endotype with potential for precision therapy.
Read More
Dupilumab Enhances Quality of Life and Relieves Respiratory Symptoms in COPD Patients with Type 2 Inflammation: Insights from BOREAS and NOTUS Trials
Posted inClinical Updates news Respiratory

Dupilumab Enhances Quality of Life and Relieves Respiratory Symptoms in COPD Patients with Type 2 Inflammation: Insights from BOREAS and NOTUS Trials

Posted by By MedXY 09/19/2025
Add-on dupilumab significantly improves health-related quality of life and respiratory symptoms in COPD patients with type 2 inflammation, according to pooled results from the BOREAS and NOTUS phase 3 trials.
Read More
Type 2 Inflammation Biomarkers and Dupilumab Response in COPD: Insights from the BOREAS Phase 3 Trial
Posted inClinical Updates Respiratory Specialties

Type 2 Inflammation Biomarkers and Dupilumab Response in COPD: Insights from the BOREAS Phase 3 Trial

Posted by By MedXY 08/02/2025
Dupilumab significantly reduced type 2 inflammation biomarkers and exacerbation risk in COPD patients with elevated eosinophils, highlighting the value of biomarker-driven therapy.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Racial and Ethnic Equity in Pediatric Perioperative Cardiac Arrest Survival: Insights from a Large National Cohort
  • Emerging Plasma Biomarkers in Systemic Sclerosis-Associated Lung Disease: Insights from High-Throughput Proteomics
  • Hepatic Artery Complications After Pediatric Liver Transplantation: Insights from the HEPATIC Registry
  • Topical Sirolimus Gel as a Novel Treatment for Hyperplastic Rosacea: Efficacy, Safety, and Innovative Volume Assessment
  • Preserving Lower Lip Function in Facial Synkinesis: Transitioning from Platysma Myectomy to Myotomy
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top